200 related articles for article (PubMed ID: 11757697)
1. New strategies for vaccination and imunomodulation in NHL.
Stevenson FK; Zhu D; Rice J
Ann Hematol; 2001; 80 Suppl 3():B132-4. PubMed ID: 11757697
[TBL] [Abstract][Full Text] [Related]
2. DNA fusion vaccines against B-cell tumors.
Zhu D; Rice J; Savelyeva N; Stevenson FK
Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
[TBL] [Abstract][Full Text] [Related]
3. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
4. Vaccination as immunotherapy for B cell lymphoma.
Schultze JL
Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.
King CA; Spellerberg MB; Zhu D; Rice J; Sahota SS; Thompsett AR; Hamblin TJ; Radl J; Stevenson FK
Nat Med; 1998 Nov; 4(11):1281-6. PubMed ID: 9809552
[TBL] [Abstract][Full Text] [Related]
7. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
Patel KG; Ng PP; Levy S; Levy R; Swartz JR
Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines against haematological malignancies.
Stevenson FK; King CA; Spellerberg MB; Zhu D; Rice J; Sahota S; Thompsett A; Radl J; Hamblin TJ
Haematologica; 1999 Jun; 84 Suppl EHA-4():11-3. PubMed ID: 10907456
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccines against cancer: from genes to therapy.
Stevenson FK
Ann Oncol; 1999 Dec; 10(12):1413-8. PubMed ID: 10643531
[TBL] [Abstract][Full Text] [Related]
11. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.
Forconi F; King CA; Sahota SS; Kennaway CK; Russell NH; Stevenson FK
Immunology; 2002 Sep; 107(1):39-45. PubMed ID: 12225361
[TBL] [Abstract][Full Text] [Related]
12. Vaccine therapy in NHL: future promises and current limitations.
Stevenson FK; King A; Ottensmeier CH
Leuk Lymphoma; 2003; 44 Suppl 3():S85-90. PubMed ID: 15202530
[TBL] [Abstract][Full Text] [Related]
13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
14. Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.
Armstrong AC; Cheadle EJ; Hawkins RE
BioDrugs; 2005; 19(5):289-97. PubMed ID: 16207070
[TBL] [Abstract][Full Text] [Related]
15. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
[TBL] [Abstract][Full Text] [Related]
16. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
Park HJ; Neelapu SS
Br J Haematol; 2008 Jun; 142(2):179-91. PubMed ID: 18422783
[TBL] [Abstract][Full Text] [Related]
17. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.
Ruffini PA; Di Nicola M; Carlo-Stella C; Siena S; Gianni AM
Curr Gene Ther; 2005 Oct; 5(5):511-21. PubMed ID: 16250891
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
19. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
